1. Siddiqui A, Dhandapani H, Rather A, Ingle A, Sharma D, Tayalia P (2026). In situ programming of CAR-macrophages via a polyplex nanomaterial and STING activation for triple-negative breast cancer immunotherapy. Nanoscale.

2. Subramani V, Chauhan, H, David S, Maitre P, Menon S, Joshi A, Misra A, Arora A, Pal M, Prakash G, Murthy V (2026). Efficacy and safety of adjuvant radiotherapy in primary resected adrenocortical carcinoma – A comparative study. Journal of UroOncology 1(1): 24-30.

3. Mirgh S, Sood K, Punatar S, Gokarn A, Chichra A, Nayak L, Bain G, Bagal B, Khattry N (2026). MRD directed consolidation in multiple myeloma – Are we there yet? Clinical Lymphoma Myeloma and Leukemia.

4. Sahu A, Mehta D, Dasgupta A, Dev I, Puranik A, Bhattacharya K, Sahay A, Sridhar E, Shetty P, Moiyadi A, Menon N, Chatterjee A, Gupta T (2026). Patterns of radiation-induced subependymal enhancement in patients with high-grade glioma. Neuroradiology Journal.

5. Karale B, Tambe M, Rajak J, D'Silva SZ (2026). Identification of the Novel HLA-B Allele, HLA-B*57:198, in an Individual From North India. HLA. 107(1):e70538.

6. Krishnamurthy Manjunath N, Patil V, Shirsat A, Wairagade S, Pradosh A, Kumar S, Jadhav S, Chavan A, Patil A, Joshi A, Prabhash K, Gota V, Noronha V (2026). A prospective, open-label, randomized, crossover study to compare the pharmacokinetics of crushed methotrexate with that of the tablet formulation in patients with head-and-neck cancer. Cancer Research, Statistics and Treatment 9(1):1-7.

7. Mirgh S, Goel A, Punatar S, Gokarn A, Jindal N, Chichra A, Nayak L, Bain G, Nashikkar C, Mahajan P, Deval K, Khan A, Tembhare P, Patkar N, Rajpal S, Chatterjee G, Kannan S, Mathew L, Subramanian P, Bagal B, Khattry N (2026). Is Less "Sufficient" and "Safe" in the MRD era - outcomes of autologous stem-cell transplant as per melphalan dose in patients with multiple myeloma. Blood Cancer Journal. 16(1):10.

ViralZone is a web resource for all viral genera and families that provides general molecular and epidemiological information, along with virion and genome figures

Mao C, Jiang D, Koong AC, Gan B. Exploiting metabolic cell death for cancer therapy. Nat Rev Cancer. 2026 26(1):27-45.

In 1996, FDA approved anastrozole (Arimidex) as a treatment for breast cancer. This drug blocks the production of estrogen.

2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)